Tango Therapeutics (TNGX) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to 26.15%.
- Tango Therapeutics' EBIT Margin rose 3094100.0% to 26.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 165.91%, marking a year-over-year increase of 1560900.0%. This contributed to the annual value of 346.09% for FY2024, which is 335100.0% down from last year.
- According to the latest figures from Q3 2025, Tango Therapeutics' EBIT Margin is 26.15%, which was up 3094100.0% from 1287.87% recorded in Q2 2025.
- Tango Therapeutics' 5-year EBIT Margin high stood at 26.15% for Q3 2025, and its period low was 1287.87% during Q2 2025.
- Moreover, its 5-year median value for EBIT Margin was 432.41% (2022), whereas its average is 440.58%.
- Data for Tango Therapeutics' EBIT Margin shows a peak YoY increase of 3094100bps (in 2025) and a maximum YoY decrease of -11391800bps (in 2025) over the last 5 years.
- Quarter analysis of 5 years shows Tango Therapeutics' EBIT Margin stood at 384.6% in 2021, then fell by -24bps to 476.79% in 2022, then crashed by -35bps to 644.69% in 2023, then tumbled by -54bps to 993.68% in 2024, then surged by 103bps to 26.15% in 2025.
- Its EBIT Margin was 26.15% in Q3 2025, compared to 1287.87% in Q2 2025 and 788.76% in Q1 2025.